Novo Nordisk plans to invest GBP 115 million in a new UK science research centre over the next ten years. The facility will eventually employ 100 scientists and academics, working on new ways to treat type 2 diabetes. Research and molecular biology will be carried out at the Oxford site, while new drugs and treatments will be developed and manufactured in Denmark. The move follows similar foreign investment in the UK's top universities in recent years, such as GBP 300 million in funding from China, Oman and Singapore granted to commercialize Oxford research.